📈 Jumpstart Signal Watchlist — September 02, 2026

🏢 What they do: Vir Biotechnology is a clinical-stage biopharmaceutical company that develops medicines for serious infectious diseases and cancer. Its work centers on immune-based therapies, including antibody-based and other platform-driven drug candidates such as programs for hepatitis delta, hepatitis B, and solid tumors.
- 🎯 Current $11.50 is 12% below 3yr high $13.11 · ⏳ SMA200 $8.44 (current price $11.50 is above) · 💰 Market Cap $1.9B
- VIR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 32/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 159% (>20%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 6/20
- 🔔 Strong above EMA21 (12.5%)
- 🔔 Strong above EMA50 (17.9%)
- 🔔 SMA20/SMA50 bullish crossover
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 69 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results — Business Wire.
🤖 Vir reported better-than-expected quarterly results, including $0.47 EPS and $238.95 million in revenue, and highlighted progress in hepatitis delta and oncology programs. The company also ended the quarter with over $1.0 billion in cash, which supports its development runway.
✅ Vir Biotechnology Q2 Earnings Call Highlights — MarketBeat.
🤖 This article emphasizes completed enrollment in the ECLIPSE registrational studies, encouraging SOLSTICE data, and progress in the Astellas collaboration. It is positive for the stock because it reinforces both clinical momentum and a strong cash position.
✅ Vir Biotechnology climbs 9% amid post-earnings uptrend — Seeking Alpha.
🤖 The stock continued rising after the company’s August 5 earnings report, reflecting investor reaction to the beat on revenue and the improved financial outlook. The article also points to upcoming catalyst-rich clinical readouts that may further support sentiment.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: MeiraGTx Holdings plc is a clinical-stage genetic medicines company that develops gene therapies and other genetic medicine platforms for both rare and more common diseases. Its work includes programs in eye diseases, Parkinson’s disease, and radiation-induced dry mouth, along with its riboswitch technology for controlled delivery of biologic therapies.
- 🎯 Current $14.06 is 6% below 3yr high $14.97 · ⏳ SMA200 $9.64 (current price $14.06 is above) · 💰 Market Cap $1.3B
- MGTX shows decent technicals supported by positive sentiment.

💎 Quality (Q): 38/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 456% (>20%); PEG ratio 0.04 (<1.5).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Jupiter Topco LLC Buys New Shares in MeiraGTx Holdings PLC $MGTX — MarketBeat.
🤖 A new institutional stake is generally supportive for sentiment because it signals outside confidence in MeiraGTx’s prospects. The article also notes the company’s strong Q2 earnings beat and continued positive analyst consensus.
✅ MeiraGTx (NASDAQ:MGTX) Upgraded by Wall Street Zen to Buy Rating — MarketBeat.
🤖 The upgrade to Buy adds a bullish analyst signal for MGTX. The article also highlights the company’s large earnings beat and favorable price-target commentary.
✅ MeiraGTx Reports Second Quarter 2026 Financial and Operational Results — Yahoo Finance / Globe Newswire.
🤖 The company reported Q2 2026 results along with positive clinical and regulatory updates, including FDA Breakthrough Therapy Designation and positive Phase 1 data. It also completed acquisition of bota-vec rights and secured strategic capital, which strengthens the story around future pipeline value.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Paysign, Inc. is a payments technology company that provides prepaid card programs, integrated payment processing, and digital banking/payment solutions for businesses, healthcare and pharmaceutical clients, and government or consumer payout programs.
- 🎯 Current $12.53 is 11% below 3yr high $14.14 · ⏳ SMA200 $6.51 (current price $12.53 is above) · 💰 Market Cap $707M
- PAYS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 49/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 450% (>20%); Revenue growth 48% (>15%); ROE 26% (>15%); Low LT D/E 0.06 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (15.5%)
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Paysign at 17th Annual Midwest IDEAS Conference: growth broadens — Investing.com.
🤖 Paysign said its plasma payments business remains a leader while its patient affordability segment is accelerating and driving more of the revenue growth. The article also reiterates strong 2026 revenue and EBITDA guidance, which is favorable for the stock.
✅ Paysign (NASDAQ:PAYS) Sets New 1-Year High — MarketBeat.
🤖 The stock hit a new 52-week high as investors reacted to strong second-quarter results and reaffirmed upbeat full-year guidance. The article also notes continued positive analyst sentiment and higher price targets.
⚪️ Paysign (NASDAQ:PAYS) Shares Down 5.3% — MarketBeat.
🤖 This item mainly reports a short-term pullback in the share price, but it also repeats the company’s earnings beat and raised guidance. The operational backdrop remains positive, so the price drop appears more trading-driven than fundamentally negative.
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: MISTRAS Group provides technology-enabled industrial asset integrity and asset protection solutions, including non-destructive testing, inspection, monitoring, and engineering services. It also offers related testing products, systems, and software for critical infrastructure and industrial assets.
- 🎯 Current $19.39 is 1% below 3yr high $19.51 · ⏳ SMA200 $15.61 (current price $19.39 is above) · 💰 Market Cap $618M
- MG shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 130% (>20%); Low LT D/E 0.72 (<1.0); PEG ratio 0.18 (<1.5).
⏰ Entry (E): 2/20
- 🔔 Strong above EMA21 (6.3%)
- 🔔 Strong above EMA50 (10.3%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 62 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Mistras Group (NYSE:MG) Hits New 1-Year High — MarketBeat.
🤖 The stock reached a new 52-week high after the company’s strong quarterly beat and improved outlook. The move suggests investors responded favorably to both the earnings performance and guidance.
✅ MISTRAS Announces Second Quarter and First Half 2026 Results — Globe Newswire.
🤖 MISTRAS reported revenue growth, higher operating income, and raised full-year guidance for revenue and adjusted EBITDA. Those results and outlook upgrades are constructive for $MG.
⚪️ Mistras Group (NYSE:MG) Downgraded to "Buy" Rating by Wall Street Zen — MarketBeat.
🤖 Wall Street Zen trimmed its rating from strong buy to buy, but the article also notes Mistras beat quarterly estimates and the broader consensus remains hold. The mixed analyst commentary makes this only mildly informative for the stock.
🍭 Bonus (B): 0/10 — Engineering Services

🏢 What they do: BioCryst Pharmaceuticals is a biotechnology company that develops and commercializes medicines for hereditary angioedema (HAE) and other rare diseases. Its key products include ORLADEYO for preventing HAE attacks and RAPIVAB for treating influenza, and it is also advancing additional rare-disease drug candidates.
- 🎯 Current $10.17 is 9% below 3yr high $11.19 · ⏳ SMA200 $8.52 (current price $10.17 is above) · 💰 Market Cap $2.6B
- BCRX shows decent technicals supported by positive sentiment.

💎 Quality (Q): 28/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1400% (>20%); Revenue growth 34% (>15%).
⏰ Entry (E): 8/20
- 🔔 SMA20/SMA50 bullish crossover
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ BioCryst Reports Second Quarter 2026 Financial Results — GlobeNewswire.
🤖 BioCryst beat Q2 expectations, raised full-year total revenue guidance, and said ORLADEYO oral pellets began shipping to pediatric patients. The update also noted completion of enrollment in the pivotal ALPHA-ORBIT study, which supports a constructive view on the stock.
✅ BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6% — MarketBeat.
🤖 This article highlights the market reacting favorably after BioCryst’s earnings beat and stronger revenue. It also points to continued supportive analyst sentiment, which is positive for the stock.
⚪️ NFJ Investment Group LLC Makes New $2.79 Million Investment in BioCryst Pharmaceuticals, Inc. $BCRX — MarketBeat.
🤖 The piece primarily reports a second-quarter investment filing rather than new operating news from BioCryst itself. It is mildly supportive as an ownership signal, but it does not materially change the business outlook.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Ooma, Inc. provides cloud-based VoIP phone systems and unified communications services for businesses and consumers, featuring voice, messaging, video, and AI tools like call transcriptions and answering services. Their primary offerings include Ooma Office for small to mid-sized businesses, Ooma AirDial for POTS line replacement, and Ooma Telo for affordable residential landline service.
- 🎯 Current $22.53 is 2% below 3yr high $23.04 · ⏳ SMA200 $15.61 (current price $22.53 is above) · 💰 Market Cap $617M
- OOMA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (14.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1000% (>20%); Revenue growth 25% (>15%); Low LT D/E 0.50 (<1.0).
⏰ Entry (E): 2/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Ooma rises 7% on Q2 earnings beat, upbeat guidance — Investing.com.
🤖 Ooma beat second-quarter profit and revenue estimates and issued guidance above consensus, which is typically supportive for the stock. The article says shares rose sharply after the results, reflecting a favorable investor reaction.
✅ Ooma Inc earnings beat by $0.02, revenue topped estimates — Investing.com.
🤖 This report highlights that Ooma exceeded analyst expectations on both earnings and revenue for the quarter. Beating estimates is generally positive for valuation and near-term sentiment.
⚪️ Ooma SVP Jenny Yeh sells $504,320 in company stock — Investing.com.
🤖 The article is mainly an insider-selling notice, but it also references Ooma’s strong fiscal second-quarter results and subsequent analyst price-target increase. Insider sales can be a mild negative signal, yet the earnings and rating context makes the overall impact mixed.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 At/above 3yr high $58.53 (current $58.53) · ⏳ SMA200 $47.33 (current price $58.53 is above) · 💰 Market Cap $14.6B
- EXEL shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 26% (>20%); ROE 47% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (6.6%)
- 📈 RSI at 64 showing strength
📢 Sentiment (S): 6/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ Exelixis Inc (EXEL) (Q2 2026) Earnings Call Highlights — Yahoo Finance.
🤖 The company reported strong Q2 2026 financial results, including about $629 million in revenue and $212 million in GAAP net income. The earnings strength is positive for the stock, although the article is mainly a summary of the quarter.
✅ BlackRock Inc. Purchases New Stake in Exelixis, Inc. $EXEL — MarketBeat.
🤖 BlackRock disclosed a large new stake in Exelixis, which can be read as a vote of confidence from a major institutional investor. The article is supportive for sentiment, though it is more ownership news than a direct operating catalyst.
❌ Exelixis (NASDAQ:EXEL) Lowered to "Buy" Rating by Wall Street Zen — MarketBeat.
🤖 Wall Street Zen downgraded Exelixis from Strong Buy to Buy, which is a modest negative signal for sentiment. The article also notes that the stock had already reacted to guidance pressure from the slower-than-expected NET launch.
⚪️ Exelixis Q2 2026 slides: strong earnings, but NET slowdown cuts guidance — Investing.com.
🤖 Exelixis reported solid Q2 2026 results with EPS above estimates, but revenue missed consensus and the company reduced its full-year revenue guidance by about $50 million at the midpoint. The mixed result and lower outlook offset the earnings beat for the stock.
⚪️ BMO Capital Markets Upgrades Exelixis (NASDAQ:EXEL) to "Hold" — MarketBeat.
🤖 BMO Capital Markets raised its rating on Exelixis to Hold, aligning with the broader analyst consensus. The upgrade is mildly supportive, but it does not signal a strong bullish change in outlook.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Magnite is an advertising technology company that provides a sell-side platform for digital advertising. Its software helps publishers and media owners manage and monetize ad inventory across channels like connected TV, video, mobile, and desktop, while also connecting them with advertisers and agencies.
- 🎯 Current $24.88 is 6% below 3yr high $26.52 · ⏳ SMA200 $15.86 (current price $24.88 is above) · 💰 Market Cap $3.6B
- MGNI shows decent technicals supported by positive sentiment.

💎 Quality (Q): 50/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 62% (>20%); ROE 18% (>15%); Low LT D/E 0.37 (<1.0); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 3/20
- 🔔 Strong above EMA21 (7.3%)
- 🔔 Strong above EMA50 (16.8%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 65 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ Has Magnite (MGNI) Already Moved Above Fair Value? — Yahoo Finance.
🤖 This article points to ongoing upside in MGNI after its recent earnings-driven move, implying the stock may still have room to run. It is supportive for the shares because it frames the valuation discussion in the context of recent momentum rather than deterioration.
✅ Magnite at Rosenblatt ai summit: ctv growth and google upside — Investing.com.
🤖 Magnite highlighted fast-growing CTV revenue and possible upside from Google-related antitrust remedies, both of which support a bullish long-term case. The article is positive for the stock because it reinforces growth and optionality themes.
⚪️ 450,000 Shares in Magnite, Inc. $MGNI Acquired by Manatuck Hill Partners LLC — MarketBeat.
🤖 The piece reports a new institutional position in Magnite, which is mildly constructive but not a direct operating catalyst. It is best read as neutral because it reflects investor interest rather than a fundamental change in the business.
⚪️ Great Lakes Advisors LLC Takes Position in Magnite, Inc. $MGNI — MarketBeat.
🤖 This filing-based article shows another institution initiating a stake in MGNI, which suggests continued demand from investors. The impact on the stock is limited because it does not add new operational or financial information.
🍭 Bonus (B): 10/10 — Computer Programming & Data Processing (Technology sector)

🏢 What they do: Remitly Global, Inc. is a digital financial services provider that offers cross-border remittance and international money transfer services primarily for immigrants and their families through a mobile app and website .
- 🎯 Current $26.82 is 3% below 3yr high $27.59 · ⏳ SMA200 $18.51 (current price $26.82 is above) · 💰 Market Cap $5.7B
- RELY shows decent technicals supported by positive sentiment.

💎 Quality (Q): 53/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 3000% (>20%); Revenue growth 20% (>15%); ROE 27% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 2/20
- 🔔 Strong above EMA50 (10.5%)
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Remitly (RELY) Is Up 7.2% After Strong Q2 Beat And Launch Of Global Multi-Currency Card — Yahoo Finance.
🤖 Remitly posted strong second-quarter results, raised full-year revenue guidance, and launched a multi-currency card product. The earnings beat and product expansion both support a bullish view of growth and diversification.
✅ Remitly Reports Record Second Quarter Results and Raises Full Year 2026 Outlook — GlobeNewswire.
🤖 The company reported record Q2 revenue, customer growth, and adjusted EBITDA, while also raising its full-year 2026 outlook. This is positive for the stock because it shows momentum and improved expectations for the rest of the year.
⚪️ Remitly global director Riese sells $6.3 m of stock — Investing.com.
🤖 The article reports insider selling by a director, but it also notes that the sales were accompanied by option exercises and occurred after strong quarterly results. The impact is mixed, so it is best treated as neutral.
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: Five9, Inc. provides cloud contact center software, including its Intelligent CX platform for managing customer interactions across voice and digital channels like chat, email, SMS, and social media. Its products also include AI, automation, analytics, and workforce optimization tools that help businesses run customer service and sales operations.
- 🎯 Current $33.59 is 61% below 3yr high $85.47 · ⏳ SMA200 $21.11 (current price $33.59 is above) · 💰 Market Cap $2.5B
- FIVN shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 300% (>20%); Low LT D/E 0.25 (<1.0); PEG ratio 0.16 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (16.0%)
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Five9 Named a Leader in the 2026 IDC MarketScape: Worldwide Agentic Contact Center-as-a-Service Platforms — Business Wire.
🤖 Five9 said it was named a Leader in an IDC MarketScape assessment, a credibility boost that can support the company’s competitive positioning and investor sentiment.
✅ Five9 (NASDAQ:FIVN) Price Target Raised to $40.00 — MarketBeat.
🤖 Truist Financial raised its price target to $40 and kept a buy rating, adding to a pattern of bullish analyst revisions that may support the stock.
⚪️ Five9 (NASDAQ:FIVN) Price Target Raised to $32.00 at Wells Fargo & Company — MarketBeat.
🤖 Wells Fargo raised its target but kept an equal weight rating, which signals improved expectations without a strongly bullish stance.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)